Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
LMAT's Cash-to-Debt is ranked higher than
92% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. LMAT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
LMAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
LMAT's Equity-to-Asset is ranked higher than
90% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. LMAT: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
LMAT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.85 Max: 0.9
Current: 0.86
0.4
0.9
Interest Coverage 1230.64
LMAT's Interest Coverage is ranked higher than
65% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. LMAT: 1230.64 )
Ranked among companies with meaningful Interest Coverage only.
LMAT' s Interest Coverage Range Over the Past 10 Years
Min: 74.96  Med: 1217.43 Max: No Debt
Current: 1230.64
Piotroski F-Score: 6
Altman Z-Score: 25.10
Beneish M-Score: -2.58
WACC vs ROIC
5.43%
20.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.52
LMAT's Operating Margin % is ranked higher than
84% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. LMAT: 18.52 )
Ranked among companies with meaningful Operating Margin % only.
LMAT' s Operating Margin % Range Over the Past 10 Years
Min: -10.33  Med: 7.08 Max: 18.52
Current: 18.52
-10.33
18.52
Net Margin % 12.52
LMAT's Net Margin % is ranked higher than
79% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. LMAT: 12.52 )
Ranked among companies with meaningful Net Margin % only.
LMAT' s Net Margin % Range Over the Past 10 Years
Min: -7.08  Med: 4.75 Max: 12.52
Current: 12.52
-7.08
12.52
ROE % 13.56
LMAT's ROE % is ranked higher than
74% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. LMAT: 13.56 )
Ranked among companies with meaningful ROE % only.
LMAT' s ROE % Range Over the Past 10 Years
Min: -7.03  Med: 5.38 Max: 13.56
Current: 13.56
-7.03
13.56
ROA % 11.67
LMAT's ROA % is ranked higher than
85% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. LMAT: 11.67 )
Ranked among companies with meaningful ROA % only.
LMAT' s ROA % Range Over the Past 10 Years
Min: -5.75  Med: 4.5 Max: 11.67
Current: 11.67
-5.75
11.67
ROC (Joel Greenblatt) % 54.49
LMAT's ROC (Joel Greenblatt) % is ranked higher than
86% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. LMAT: 54.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LMAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24.38  Med: 22.89 Max: 54.5
Current: 54.49
-24.38
54.5
3-Year Revenue Growth Rate 4.20
LMAT's 3-Year Revenue Growth Rate is ranked higher than
51% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. LMAT: 4.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LMAT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.9  Med: 5 Max: 21.4
Current: 4.2
-4.9
21.4
3-Year EBITDA Growth Rate 31.60
LMAT's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. LMAT: 31.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LMAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.15 Max: 31.6
Current: 31.6
0
31.6
3-Year EPS without NRI Growth Rate 40.10
LMAT's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. LMAT: 40.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LMAT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -45.9  Med: 20.9 Max: 55.4
Current: 40.1
-45.9
55.4
GuruFocus has detected 5 Warning Signs with LeMaitre Vascular Inc $LMAT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LMAT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

LMAT Guru Trades in Q2 2016

Columbia Wanger 559,839 sh (+887.89%)
Jim Simons 99,300 sh (-20.30%)
» More
Q3 2016

LMAT Guru Trades in Q3 2016

Jim Simons 183,500 sh (+84.79%)
Columbia Wanger 633,128 sh (+13.09%)
» More
Q4 2016

LMAT Guru Trades in Q4 2016

Columbia Wanger 904,295 sh (+42.83%)
Jim Simons 119,100 sh (-35.10%)
» More
Q1 2017

LMAT Guru Trades in Q1 2017

Jim Simons 183,300 sh (+53.90%)
Columbia Wanger 1,093,903 sh (+20.97%)
» More
» Details

Insider Trades

Latest Guru Trades with LMAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:MLAB, NAS:ANGO, AMEX:CRHM, NAS:ATRC, NAS:PLSE, NAS:ELGX, NAS:ATRS, NAS:STAA, NAS:IRTC, NAS:ENTL, NAS:OSUR, NAS:UTMD, NAS:LMNX, NAS:DSCI, NAS:CFMS, NAS:SIEN, NAS:ATRI, NAS:IVTY, NAS:MBOT, NAS:LAKE » details
Traded in other countries:LHU.Germany,
Headquarter Location:USA
LeMaitre Vascular Inc provides medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons.

LeMaitre manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States. Sales in Germany also contribute a significant proportion of total revenue.

Top Ranked Articles about LeMaitre Vascular Inc

LeMaitre Vascular to Present at Upcoming Investor Conferences
LeMaitre Vascular Will Announce First Quarter 2017 Earnings Results on April 26, 2017
LeMaitre Vascular to Present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017
LeMaitre Vascular to Present at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29, 2017
BURLINGTON, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at Sidoti & Company Spring 2017 Convention on Wednesday, March 29, 2017 at the Marriott Marquis, New York City, NY.
The Company is scheduled to present at 11:35 a.m. EDT.About LeMaitre VascularLeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact:  LeMaitre Vascular, Inc.
Investor Relations
Steven Chehames
1-781-425-1659
[email protected]

Read more...
LeMaitre Vascular to Present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017

BURLINGTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at the Loews Miami Beach Hotel in Miami Beach, FL.
The Company is scheduled to present at 4:50 p.m. EDT. About LeMaitre Vascular LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.  

Contact: LeMaitre Vascular, Inc.
Investor Relations
Steven Chehames
1-781-425-1659
[email protected]

Read more...
LeMaitre Vascular to Present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017

BURLINGTON, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at 29th Annual ROTH Conference on Tuesday, March 14, 2017 at the Ritz-Carlton, Laguna Niguel, CA.
The Company is scheduled to present at 9:00 a.m. PDT. About LeMaitre Vascular LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact:  LeMaitre Vascular, Inc.
Investor Relations
Steven Chehames
1-781-425-1659
[email protected]

Read more...
LeMaitre Vascular to Present at the Cowen & Company 37th Annual Health Care Conference on March 6, 2017

BURLINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Cowen & Company Annual Health Care Conference on Monday, March 6, 2017 at the Marriott Copley Place in Boston, MA.
The Company is scheduled to present at 4:40 p.m. EST. About LeMaitre Vascular LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: 
LeMaitre Vascular, Inc.
Investor Relations
Steven Chehames
1-781-425-1659
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 50.35
LMAT's PE Ratio is ranked lower than
73% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. LMAT: 50.35 )
Ranked among companies with meaningful PE Ratio only.
LMAT' s PE Ratio Range Over the Past 10 Years
Min: 15.93  Med: 35.67 Max: 125
Current: 50.35
15.93
125
Forward PE Ratio 43.86
LMAT's Forward PE Ratio is ranked lower than
82% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. LMAT: 43.86 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 50.35
LMAT's PE Ratio without NRI is ranked lower than
73% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. LMAT: 50.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
LMAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.93  Med: 35.67 Max: 125
Current: 50.35
15.93
125
Price-to-Owner-Earnings 44.36
LMAT's Price-to-Owner-Earnings is ranked lower than
63% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. LMAT: 44.36 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LMAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.22  Med: 40.67 Max: 3485
Current: 44.36
12.22
3485
PB Ratio 6.16
LMAT's PB Ratio is ranked lower than
69% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. LMAT: 6.16 )
Ranked among companies with meaningful PB Ratio only.
LMAT' s PB Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.89 Max: 6.52
Current: 6.16
0.67
6.52
PS Ratio 6.30
LMAT's PS Ratio is ranked lower than
67% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. LMAT: 6.30 )
Ranked among companies with meaningful PS Ratio only.
LMAT' s PS Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.81 Max: 6.67
Current: 6.3
0.62
6.67
Price-to-Free-Cash-Flow 40.71
LMAT's Price-to-Free-Cash-Flow is ranked lower than
60% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. LMAT: 40.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LMAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.2  Med: 32.29 Max: 112.19
Current: 40.71
9.2
112.19
Price-to-Operating-Cash-Flow 32.24
LMAT's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. LMAT: 32.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LMAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.29  Med: 23.48 Max: 63.61
Current: 32.24
8.29
63.61
EV-to-EBIT 31.55
LMAT's EV-to-EBIT is ranked lower than
61% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. LMAT: 31.55 )
Ranked among companies with meaningful EV-to-EBIT only.
LMAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -284.5  Med: 18.95 Max: 60.7
Current: 31.55
-284.5
60.7
EV-to-EBITDA 25.97
LMAT's EV-to-EBITDA is ranked lower than
71% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. LMAT: 25.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.7  Med: 13.75 Max: 2641.2
Current: 25.97
-174.7
2641.2
PEG Ratio 2.08
LMAT's PEG Ratio is ranked higher than
69% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. LMAT: 2.08 )
Ranked among companies with meaningful PEG Ratio only.
LMAT' s PEG Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.96 Max: 3.95
Current: 2.08
1.02
3.95
Shiller PE Ratio 149.42
LMAT's Shiller PE Ratio is ranked lower than
93% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. LMAT: 149.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
LMAT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 97.29  Med: 131.36 Max: 178
Current: 149.42
97.29
178
Current Ratio 5.81
LMAT's Current Ratio is ranked higher than
85% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. LMAT: 5.81 )
Ranked among companies with meaningful Current Ratio only.
LMAT' s Current Ratio Range Over the Past 10 Years
Min: 1.39  Med: 5.55 Max: 8.76
Current: 5.81
1.39
8.76
Quick Ratio 4.14
LMAT's Quick Ratio is ranked higher than
83% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. LMAT: 4.14 )
Ranked among companies with meaningful Quick Ratio only.
LMAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 4.04 Max: 7.26
Current: 4.14
0.73
7.26
Days Inventory 234.73
LMAT's Days Inventory is ranked lower than
83% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. LMAT: 234.73 )
Ranked among companies with meaningful Days Inventory only.
LMAT' s Days Inventory Range Over the Past 10 Years
Min: 171.21  Med: 220.44 Max: 266.3
Current: 234.73
171.21
266.3
Days Sales Outstanding 55.28
LMAT's Days Sales Outstanding is ranked higher than
65% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. LMAT: 55.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.01  Med: 55.62 Max: 61.82
Current: 55.28
54.01
61.82
Days Payable 29.90
LMAT's Days Payable is ranked lower than
95% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. LMAT: 29.90 )
Ranked among companies with meaningful Days Payable only.
LMAT' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 21.91 Max: 77.19
Current: 29.9
14.93
77.19

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.66
LMAT's Dividend Yield % is ranked lower than
74% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. LMAT: 0.66 )
Ranked among companies with meaningful Dividend Yield % only.
LMAT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 1.43 Max: 1.98
Current: 0.66
0.28
1.98
Dividend Payout Ratio 0.32
LMAT's Dividend Payout Ratio is ranked lower than
58% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. LMAT: 0.32 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LMAT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.6 Max: 0.63
Current: 0.32
0.32
0.63
3-Year Dividend Growth Rate 14.50
LMAT's 3-Year Dividend Growth Rate is ranked higher than
64% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. LMAT: 14.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LMAT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 20.5
Current: 14.5
0
20.5
Forward Dividend Yield % 0.73
LMAT's Forward Dividend Yield % is ranked lower than
77% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. LMAT: 0.73 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.47
LMAT's 5-Year Yield-on-Cost % is ranked lower than
53% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. LMAT: 1.47 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LMAT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.62  Med: 3.19 Max: 4.42
Current: 1.47
0.62
4.42
3-Year Average Share Buyback Ratio -6.00
LMAT's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. LMAT: -6.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LMAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26  Med: -4.3 Max: 1
Current: -6
-26
1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 52.09
LMAT's Price-to-Net-Cash is ranked lower than
81% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. LMAT: 52.09 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LMAT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.85  Med: 8.73 Max: 160.2
Current: 52.09
2.85
160.2
Price-to-Net-Current-Asset-Value 11.85
LMAT's Price-to-Net-Current-Asset-Value is ranked lower than
61% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. LMAT: 11.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LMAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.27  Med: 3.26 Max: 11.85
Current: 11.85
1.27
11.85
Price-to-Tangible-Book 9.65
LMAT's Price-to-Tangible-Book is ranked lower than
72% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. LMAT: 9.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LMAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.13  Med: 2.83 Max: 9.65
Current: 9.65
1.13
9.65
Price-to-Intrinsic-Value-Projected-FCF 3.61
LMAT's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
66% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. LMAT: 3.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LMAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.42  Med: 1.92 Max: 3.61
Current: 3.61
1.42
3.61
Price-to-Median-PS-Value 3.48
LMAT's Price-to-Median-PS-Value is ranked lower than
95% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. LMAT: 3.48 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LMAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 1.01 Max: 3.48
Current: 3.48
0.41
3.48
Price-to-Peter-Lynch-Fair-Value 2.01
LMAT's Price-to-Peter-Lynch-Fair-Value is ranked higher than
64% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.21 vs. LMAT: 2.01 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LMAT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.16  Med: 1.91 Max: 3.7
Current: 2.01
1.16
3.7
Price-to-Graham-Number 4.65
LMAT's Price-to-Graham-Number is ranked lower than
75% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. LMAT: 4.65 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LMAT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.21  Med: 2.23 Max: 4.65
Current: 4.65
1.21
4.65
Earnings Yield (Greenblatt) % 3.17
LMAT's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. LMAT: 3.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LMAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 4.6 Max: 10.9
Current: 3.17
1.6
10.9
Forward Rate of Return (Yacktman) % 26.49
LMAT's Forward Rate of Return (Yacktman) % is ranked higher than
82% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. LMAT: 26.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LMAT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.3  Med: 3 Max: 29.6
Current: 26.49
-2.3
29.6

More Statistics

Revenue (TTM) (Mil) $93.03
EPS (TTM) $ 0.60
Beta0.53
Short Percentage of Float2.36%
52-Week Range $13.52 - 33.22
Shares Outstanding (Mil)18.81

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 100 110 124
EPS ($) 0.69 0.81 0.97
EPS without NRI ($) 0.69 0.81 0.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for LMAT

Headlines

Articles On GuruFocus.com
LeMaitre Vascular to Present at Upcoming Investor Conferences May 11 2017 
LeMaitre Vascular Set to Join S&P SmallCap 600 May 01 2017 
LeMaitre Vascular Will Announce First Quarter 2017 Earnings Results on April 26, 2017 Apr 12 2017 
LeMaitre Vascular to Present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2 Mar 31 2017 
LeMaitre Vascular to Present at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29, Mar 23 2017 
LeMaitre Vascular to Present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 Mar 09 2017 
LeMaitre Vascular to Present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017 Mar 08 2017 
LeMaitre Vascular to Present at the Cowen & Company 37th Annual Health Care Conference on March 6, 2 Mar 01 2017 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 10 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Aug 12 2010 

More From Other Websites
Time to Focus on LeMaitre Vascular (LMAT) for Strong Earnings Growth Potential May 15 2017
LeMaitre Vascular to Present at Upcoming Investor Conferences May 11 2017
7 Stocks to Buy with Impressive Interest Coverage Ratio May 11 2017
Can The Uptrend Continue for LeMaitre Vascular (LMAT)? May 09 2017
Edited Transcript of LMAT earnings conference call or presentation 26-Apr-17 9:00pm GMT May 05 2017
LeMaitre Vascular Set to Join S&P SmallCap 600 May 01 2017
LeMaitre Vascular, Inc.: Leads amongst peers with strong fundamentals Apr 28 2017
Diagnostic Kit Maker Tests Resistance In Base; Gets Rating Upgrade Apr 28 2017
Top Ranked Momentum Stocks to Buy for April 28th Apr 28 2017
Here's Why LeMaitre Vascular Stock Is Soaring Today Apr 27 2017
LeMaitre tops Street 1Q forecasts Apr 26 2017
LeMaitre Q1 2017 Record Sales $24.1 mm (+19%), Net Income $3.2 mm (+49%) Apr 26 2017
Medical Device Stocks to Beat Estimates this Earnings Season Apr 18 2017
LeMaitre Vascular Will Announce First Quarter 2017 Earnings Results on April 26, 2017 Apr 12 2017
LeMaitre Vascular to Present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4,... Mar 31 2017
LeMaitre Vascular to Present at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29,... Mar 23 2017
LeMaitre Vascular to Present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 Mar 09 2017
LeMaitre Vascular to Present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017 Mar 08 2017
LeMaitre Vascular to Present at the Cowen & Company 37th Annual Health Care Conference on March 6,... Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)